- Home
- Publications
- Publication Search
- Publication Details
Title
Updating progress in sarcoma therapy with mTOR inhibitors
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 22, Issue 2, Pages 280-287
Publisher
Oxford University Press (OUP)
Online
2010-07-01
DOI
10.1093/annonc/mdq307
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
- (2011) Giovanni Ligresti et al. CELL CYCLE
- Targeting the mammalian target of rapamycin in myxoid chondrosarcoma
- (2010) Ofer Merimsky et al. ANTI-CANCER DRUGS
- The molecular mechanisms that underlie the tumor suppressor function of LKB1
- (2009) D. Fan et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
- (2009) Silvia La Monica et al. BIOCHEMICAL PHARMACOLOGY
- Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
- (2009) Eva Juengel et al. BMC CANCER
- A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
- (2009) C. M. Hartford et al. CLINICAL CANCER RESEARCH
- Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?
- (2009) Bengt Nilsson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
- (2009) Axel Le Cesne et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)
- (2009) Maleddu ONCOLOGY REPORTS
- Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
- (2009) Kwong-Kwok Wong Recent Patents on Anti-Cancer Drug Discovery
- Activated Akt Prevents Antitumor Activity of Gefitinib in Renal Cancer Cells
- (2009) Kenji Kuroda et al. UROLOGY
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
- (2008) R Bianco et al. BRITISH JOURNAL OF CANCER
- Role of LKB1 in lung cancer development
- (2008) L Makowski et al. BRITISH JOURNAL OF CANCER
- The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
- (2008) G.F.L. Hofbauer et al. BRITISH JOURNAL OF DERMATOLOGY
- Genetic aberrations of gastrointestinal stromal tumors
- (2008) Jilong Yang et al. CANCER
- RAS: Target for Cancer Therapy
- (2008) Nandita Saxena et al. CANCER INVESTIGATION
- Targeting Apoptosis Resistance in Rhabdomyosarcoma
- (2008) Simone Fulda CURRENT CANCER DRUG TARGETS
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
- (2008) Bing-Hua Jiang et al. DRUG RESISTANCE UPDATES
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
- (2008) Monica Mita et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin Treatment
- (2008) Judith M. Morton et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis
- (2008) D. Mark Davies et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Sirolimus in Treating Tuberous Sclerosis and Lymphangioleiomyomatosis
- (2008) Elahna Paul et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design
- (2008) C. C. Jaffe ONCOLOGIST
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now